Three Neurologic Societies, Including the AAN, Issue Strong Position Statement on Aducanumab.
24 Nov, 2021 | 08:36h | UTCRelated:
Editorial: Aducanumab for Alzheimer’s disease?
FDA approvement of Alzheimer’s drug sparks controversy among doctors.
Commentary on Twitter
Decisions With Patients and Families Regarding #Aducanumab in Alzheimer Disease, With Recommendations for Consent—Read the full AAN @AANMember Position Statement: https://t.co/ckoIVRi4DE #Neurology pic.twitter.com/q8TSU67zm9
— Neurology Journal (@GreenJournal) November 19, 2021